Table 2

Characteristics of cases and control samples

European studyAfrican study
Cases (n=422)Control (n=503)P valuesCases (n=118)Control (n=12)P values
Mean age (SD)50.4 (14.3)47.9 (15.7)0.02NDNDN/A
Male sex (%)254/380 (66.8)272/433 (62.8)0.2NDNDN/A
Study site
  Paris221 (52.4)190 (37.8)<0.001N/AN/AN/A
  Nottingham201 (47.6)313 (62.2)N/AN/AN/A
Positive anti-HCV at baseline (%)422/422 (100)0/503 (0)1.0NDNDN/A
Mean HCV RNA (log10 IU/mL) (SD)5.7 (1.0)N/AN/A5.3 (0.8)N/AN/A
HCV RNA (log10 IU/mL) (%)
 <3.013 (3.1)N/AN/A0N/AN/A
  3.0–6.0227 (53.8)N/A99 (83.9)N/A
 ≥6.0182 (43.1)N/A19 (16.1)N/A
HCV genotype (%)
  1301 (71.3)N/AN/A65 (55.1)N/AN/A
  24 (1.0)N/A6 (5.1)N/A
  359 (14.0)N/A7 (5.9)N/A
  431 (7.3)N/A32 (27.1)N/A
  52 (0.5)N/A6 (5.1)N/A
  Not determined25 (5.9)N/A2 (1.7)N/A
HIV infection0/42229/503NDNDN/A
HBV infection0/42225/503NDNDN/A
  • HCV, hepatitis C virus; N/A, not applicable; ND, no data.